



Pathogenesis and Novel Therapeutics in Breast Cancer

Guest Editor:

Prof. Dr. Wolfgang Würfel

INTELLEXON GmbH,
Keltenstrasse 27, 82343 Pöcking,
Germany

Deadline for manuscript
submissions:

closed (20 November 2024)

Message from the Guest Editor

In most industrialized countries breast cancer has become the most common form of cancer in women, with incidence rates continuing to rise. In recent years, immunological treatment strategies, such as the use of antibodies against HER2/neu and receptor-targeted antibody strategies, have become well-established strands of breast cancer treatment.

New treatment strategies are also emerging, including CAR T-cell therapy. Furthermore, checkpoint inhibitor treatment is now regarded as an essential element in the treatment of specific breast cancer subentities, and new treatment strategies are in preparation in all areas. In fact, the link to hormonal regulation (comparisons of hormone-receptor-positive with hormone-receptor-negative carcinomas) is an amalgamation of two major control principles of the human organism, which is, as of now, not fully understood. The field of pure immunology likewise still poses many unanswered questions. This Special Issue thus aims to present further findings in the pathogenesis of breast cancer and evaluate new treatment strategies, whether immunological, hormonal, or new strategies in radio- and chemotherapy.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. José L. Quiles

Department of Physiology,
Institute of Nutrition and Food
Technology “Jose Mataix”,
Biomedical Research Center,
University of Granada, Avda.
Conocimiento s/n, 18100 Armilla,
Granada, Spain

Message from the Editor-in-Chief

The *International Journal of Molecular Sciences (IJMS)* is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, and molecular biophysics. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Contact Us

*International Journal of Molecular
Sciences* Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/ijms
ijms@mdpi.com
X@IJMS_MDPI